AI-generated · cited to primary sources · not investment advice
Viyash Scientific (512529) Feb 2026 Filing Analysis
Does management do what it says?
SeQuent's standalone API sales for Q2 FY26 were INR 83 crore (830 Mn), failing to meet the INR 100 crore quarterly run rate target. (1 missed across 1 tracked commitment)
“And also most important factor to sustain US business today is a fully vertical or backward integrated for all our key products. We are done for almost all our key products 45% of our volume products we are done.”
The company is focusing on CDMO opportunities, expecting to generate INR 70-90 crores from this segment in the current year. — target: INR 70-90 crores (+2 more commitments)
“this year we will end up doing 70 crores to 90 crores on CDMO. It's either CDMO or CMO for big players. This year it's going to go INR 70 crores-INR 90 crores.”
Targeting the 2025-2030 patent cliff opportunity estimated at $250bn-300bn. — target: $250bn-300bn opportunity
“2025-2030 patent cliff: Large number of APIs coming off patent... estimated opportunity of ~$250bn-300bn”
The company is initiating a new distribution agreement with Boehringer Ingelheim to distribute companion animal products in India starting February. — target: N/A (+2 more commitments)
“And as you know, we have already signed an exclusive distribution agreement with the Boehringer Ingelheim... We are going to start distributing sometime in February and this is a one opportunity for expand to entire companion animal business in India.”
See the full cited Management analysis of Viyash Scientific
How durable is the business?
The regulatory moat has expanded significantly. The combined entity now boasts 15 manufacturing plants, 10 of which are USFDA approved, up from the previous count of 10 total facilities. (3 expanding)
“Combined API Manufacturing Network : 10 facilities with global approvals... US FDA, EU GMP, WHO GMP, KFDA, ANVISA, PMDA”
The moat is being strengthened through the proposed merger with Viyash Life Sciences, which brings high backward integration and cost leadership in large volume products. (5 expanding)
“most important factor to sustain US business today is a fully vertical or backward integrated for all our key products. We are done for almost all our key products 45% of our volume products we are done.”
The Formulations segment continues to be the primary growth engine, with revenue increasing to ₹11,858 million for FY25, representing a 19% YoY growth. Its share of total global sales remains dominant at approximately 77%. (5 expanding)
“Europe 1,790 [Q3 FY26] ... YoY Gr% 34%”
The company has significantly strengthened its distribution moat in India through an exclusive agreement with global giant Boehringer Ingelheim for pet products. (1 expanding across 2 engines)
“Formulations revenue grew 20% to 4.8 billion. While API revenue rose 2.9% to 3.6 billion.”
The R&D moat is expanding with the addition of Viyash's capabilities, bringing the total R&D resource count to over 200 and focusing on complex generics and oncology. (3 expanding, 1 shifted)
“Roughly we have 200 plus scientists including 20 plus doctorates and we have dedicated support team for CDMO... having specialized capabilities such as cytotoxic handling and process safety infrastructure.”
See the full cited Business Model analysis of Viyash Scientific
Where does growth come from?
The combined entity (SeQuent + Viyash) is showing accelerating revenue growth, with the full year FY25 reaching ₹30,094 Million, a 12.3% increase over the previous year. (5 accelerating across 5 signals, 1 leading indicator)
“Revenue from operations for Q3 FY'26 was INR 858 crores grown up by 11% year-on-year.”
Viyash continues to improve its gross margins through vertical integration, with Q1 FY26 gross profit margins reaching 58.0%, up from 53.5% in the prior year. (2 accelerating, 2 new trend, 1 steady across 5 signals, 1 leading indicator)
“And also most important factor to sustain US business today is a fully vertical or backward integrated for all our key products. We are done for almost all our key products 45% of our volume products we are done.”
The CDMO segment is a new and accelerating trend for the company, with 3 new contracts signed recently and a focus on complex generics and innovator life cycle management. (1 accelerating, 4 new trend across 5 signals, 1 leading indicator)
“CDMO market size in India ($Bn) 2024: 23, 2029: 45 (2x)”
The company is actively positioning its R&D pipeline to capture the patent cliff, with 25+ products currently in the Viyash R&D pipeline and 10+ First-to-File (FTF) products in the new portfolio. (4 new trend across 4 signals)
“2025-2030 patent cliff: Large number of APIs coming off patent... estimated opportunity of ~$250bn-300bn”
Formulations growth is accelerating, particularly in Emerging Markets which saw a 42% YoY jump in Q4 FY25, while the overall segment grew 19% for the full year. (5 accelerating across 5 signals, 2 leading indicators)
“Formulations 4,809 4,009 20%”
See the full cited Future Growth analysis of Viyash Scientific
What could break the thesis?
The company successfully cleared audits by key customers and maintained its 10 USFDA approved plants. Viyash completed 3 regulatory audits and 28 customer audits in Q4 FY25 without reported adverse findings. (5 stable, 1 high-severity)
“3 Regulatory Audits 45 Customer audits Facility Inspections”
Exceptional items remain a significant drag on reported profits, totaling INR 1,029 Mn for the combined entity in FY25, primarily driven by merger expenses and contractual bonuses. (2 intensifying, 3 easing, 2 high-severity)
“Net debt-to-EBITDA has reduced to less than 4x, a significant strengthening versus the previous year.”
Viyash saw a 3% sequential revenue decline due to inventory buildup at a customer's end for the US formulation facility, confirming ongoing demand/phasing volatility in this segment. (2 intensifying, 1 easing, 2 stable)
“initially post COVID there is a lot of stock build up. There is a lot of competition coming from India. That's initially we struggled a little bit on competing the cost from US side.”
The risk is stable; while timelines remain long (12-24 months for some processes), the company received 5 API approvals and 1 finished dose approval this quarter. (2 stable)
“Some of those things started getting approval next few months but as I explained last call also, it takes 4 months to 18 months.”
See the full cited Risk analysis of Viyash Scientific
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.